Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo ...

Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in ...

New research links childhood adversity with later attention deficits, sleep disruptions, and specific dopamine imbalances in ...

New research on the effects of adversity in childhood ties together stress, sleep loss, and attention deficits later in life.

Brendon Yee, PhD, professor and respiratory and sleep physician, Woolcock Institute of Medical Research, discusses the ...

The stocks for both Swiss and Israeli biotechs were up over 20% after the companies signed a merger agreement.

Stifel upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. After a deep dive on the orexin space, the firm says ...

周一，Stifel对Alkermes (NASDAQ:ALKS)采取了看多行动，将其股票评级从持有上调至买入，并将目标价从之前的25美元大幅上调至36美元。这次上调是在对公司的orexin项目，特别是ALKS2680候选药物进行深入分析后做出的。 Stifel分析师强烈相信ALKS2680在治疗1型嗜睡症（NT1）方面的潜在成功，以及其与竞争对手TAK-861的差异化。这种乐观情绪还延伸到ALKS ...

NLS Pharmaceutics shares are moving higher on Monday after the company announced it entered into a definitive merger ...

Imagine repeatedly falling asleep or falling down paralyzed when laughing or startled. This is life with narcolepsy, which can be triggered by an infection or the flu.

Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – provides an update on ...